PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibition and Stroke Prevention: Another Step Forward
- PMID: 32312221
- DOI: 10.1161/STROKEAHA.120.028567
PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibition and Stroke Prevention: Another Step Forward
Erratum in
-
Correction to: PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibition and Stroke Prevention: Another Step Forward.Stroke. 2020 Nov;51(11):e348. doi: 10.1161/STR.0000000000000352. Epub 2020 Oct 26. Stroke. 2020. PMID: 33104492 No abstract available.
Keywords: Editorials; atrial fibrillation; cardiovascular disease; evolocumab; sample size; secondary prevention; stroke.
Comment on
-
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.Stroke. 2020 May;51(5):1546-1554. doi: 10.1161/STROKEAHA.119.027759. Epub 2020 Apr 21. Stroke. 2020. PMID: 32312223 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous